NeuroBo Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on novel treatments for neurodegenerative diseases. The company's novel lead candidate NB-01 is a drug candidate for diabetic neuropathic pain. NB-02 focuses on the treatment of neurodegenerative diseases. NeuroBo Pharmaceuticals Inc., formerly known as Gemphire Therapeutics Inc., is based in Northville, United States.
Revenue (Most Recent Fiscal Year) | -- |
Net Income (Most Recent Fiscal Year) | $-12.47M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.88 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -- |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -59.42% |
Return on Assets (Trailing 12 Months) | -45.40% |
Current Ratio (Most Recent Fiscal Quarter) | 3.78 |
Quick Ratio (Most Recent Fiscal Quarter) | 3.78 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $3.44 |
Earnings per Share (Most Recent Fiscal Quarter) | -- |
Earnings per Share (Most Recent Fiscal Year) | $-2.46 |
Diluted Earnings per Share (Trailing 12 Months) | -- |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 4.91M |
Free Float | 4.87M |
Market Capitalization | $14.82M |
Average Volume (Last 20 Days) | 0.03M |
Beta (Past 60 Months) | -0.25 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 0.79% |
Percentage Held By Institutions (Latest 13F Reports) | 1.37% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |